Terms: = Ovarian cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207
2175 results:
1. Dual‑regulated oncolytic adenovirus carrying
Zhao T; Ye W; Zhang R; Zhu X; Shi Q; Xu X; Chen W; Xu L; Meng Y
Mol Med Rep; 2024 Jul; 30(1):. PubMed ID: 38757346
[TBL] [Abstract] [Full Text] [Related]
2. Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the RORα/ECM1/VEGFR2 signaling axis.
Wang M; Yuan C; Wu Z; Xu M; Chen Z; Yao J; Que Z; Tian J; Leung EL; Wang Z
Int J Biol Sci; 2024; 20(7):2454-2475. PubMed ID: 38725854
[TBL] [Abstract] [Full Text] [Related]
3. [Study of antitumor effects of human placenta hydrolysate on PC-3, OAW-42, BT-474 cell cultures].
Gromova OA; Filimonova MV; Torshin IY; Frolova DЕ
Ter Arkh; 2024 Apr; 96(3):266-272. PubMed ID: 38713042
[TBL] [Abstract] [Full Text] [Related]
4. Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors.
Fu XP; Ji CY; Tang WQ; Yu TT; Luo L
Clin Exp Med; 2024 May; 24(1):93. PubMed ID: 38693424
[TBL] [Abstract] [Full Text] [Related]
5. Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis.
Liang H; Geng S; Wang Y; Fang Q; Xin Y; Li Y
J Cell Mol Med; 2024 May; 28(9):e18315. PubMed ID: 38680032
[TBL] [Abstract] [Full Text] [Related]
6. Endometriosis-Associated ovarian cancer: From Molecular Pathologies to Clinical Relevance.
Steinbuch SC; Lüß AM; Eltrop S; Götte M; Kiesel L
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673891
[TBL] [Abstract] [Full Text] [Related]
7. MATN2 overexpression suppresses tumor growth in ovarian cancer via PTEN/PI3K/akt pathway.
Liu J; Zhang J; Zhang Y; Yang B; Liu H; Chen Y
Funct Integr Genomics; 2024 Apr; 24(2):71. PubMed ID: 38568332
[TBL] [Abstract] [Full Text] [Related]
8. A miRNA-7704/IL2RB/akt feedback loop regulates tumorigenesis and chemoresistance in ovarian cancer.
Meng X; Liang X; Yang S; Wu D; Wang X
Exp Cell Res; 2024 Apr; 437(2):114012. PubMed ID: 38565343
[TBL] [Abstract] [Full Text] [Related]
9. Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1.
Xia Y; Wang S; Sun Y; Wang W; Chang S; Zhang Z; Zhao C
Cell Commun Signal; 2024 Mar; 22(1):194. PubMed ID: 38539211
[TBL] [Abstract] [Full Text] [Related]
10. Diosgenin inhibits proliferation and migration of ovarian cancer cells and induce apoptosis via upregulation of PTEN.
Fang F; Zhang X; Fang Y
Chem Biol Drug Des; 2024 Mar; 103(3):e14459. PubMed ID: 38538058
[TBL] [Abstract] [Full Text] [Related]
11. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer.
Wang F; Yu X; Qian J; Cao Y; Dong S; Zhan S; Lu Z; Bast RC; Song Q; Chen Y; Zhang Y; Zhou J
Drug Resist Updat; 2024 May; 74():101077. PubMed ID: 38518726
[TBL] [Abstract] [Full Text] [Related]
12. The roles of autophagy, ferroptosis and pyroptosis in the anti-ovarian cancer mechanism of harmine and their crosstalk.
Zhu J; Zhu H; Zhu Q; Xu SL; Xiao L; Zhang MY; Gao J
Sci Rep; 2024 Mar; 14(1):6504. PubMed ID: 38499622
[TBL] [Abstract] [Full Text] [Related]
13. PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.
Rausio H; Cervera A; Heuser VD; West G; Oikkonen J; Pianfetti E; Lovino M; Ficarra E; Taimen P; Hynninen J; Lehtonen R; Hautaniemi S; Carpén O; Huhtinen K
Neoplasia; 2024 May; 51():100987. PubMed ID: 38489912
[TBL] [Abstract] [Full Text] [Related]
14. akting on R Loops Makes for an ATractive Target in ovarian cancer Therapy.
Ramanarayanan V; Oberdoerffer P
Cancer Res; 2024 Mar; 84(6):793-795. PubMed ID: 38486481
[TBL] [Abstract] [Full Text] [Related]
15. TOP2A modulates signaling via the akt/mTOR pathway to promote ovarian cancer cell proliferation.
Zhang K; Zheng X; Sun Y; Feng X; Wu X; Liu W; Gao C; Yan Y; Tian W; Wang Y
Cancer Biol Ther; 2024 Dec; 25(1):2325126. PubMed ID: 38445610
[TBL] [Abstract] [Full Text] [Related]
16. Periostin's role in uterine leiomyoma development: a mini-review on the potential periostin poses as a pharmacological intervention for uterine leiomyoma.
Kiesler ZG; Hunter MI; Balboula AZ; Patterson AL
Arch Gynecol Obstet; 2024 May; 309(5):1825-1831. PubMed ID: 38441600
[TBL] [Abstract] [Full Text] [Related]
17. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer.
Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM
Cancer Gene Ther; 2024 May; 31(5):721-735. PubMed ID: 38424218
[TBL] [Abstract] [Full Text] [Related]
18. TMED3 stabilizes SMAD2 by counteracting NEDD4-mediated ubiquitination to promote ovarian cancer.
Chen X; Zhang W; Han X; Li X; Xia L; Wu Y; Zhou Y
Mol Carcinog; 2024 May; 63(5):803-816. PubMed ID: 38411267
[TBL] [Abstract] [Full Text] [Related]
19. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-akt pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
20. The miR-1290/OGN axis in ovarian cancer-associated fibroblasts modulates cancer cell proliferation and invasion.
Jiang B; Xiao S; Zhang S; Xiao F
J Ovarian Res; 2024 Feb; 17(1):52. PubMed ID: 38402185
[TBL] [Abstract] [Full Text] [Related]
[Next]
